SQZ Biotech to Present First Time Data Demonstrating Potential of Company’s Second Novel Cell Therapy Approach in Oncology – Activating Antigen Carriers (AACs)
Preclinical data demonstrate SQZ AACs ability to prime antigen-specific T cell responses and drive tumor reduction in vivo
SQZ to also present additional preclinical data on company’s first oncology approach with SQZPBMC-HPV
WATERTOWN, Mass., Nov. 5, 2019 — SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing innovative treatments for multiple therapeutic areas, today announced the first data highlighting the potential of the company’s activating antigen carrier (AAC) immunotherapy program for oncology indications. The findings will be detailed in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting. SQZ AACs are part of SQZ’s immune-oncology pipeline, which also includes SQZ Antigen Presenting Cells (APCs).
First program advancing into the clinic through the SQZ-Roche collaboration in APCs for oncology
WATERTOWN, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) — SQZ Biotechnologies (SQZ), a cell therapy company developing innovative treatments for multiple therapeutic areas, today announced that the company’s Investigational New Drug (IND) application for SQZ-PBMC-HPV, a novel cellular immunotherapy of antigen presenting cells (APCs) has been cleared after submission to the U.S. Food and Drug Administration (FDA).
WALTHAM, Mass., — August 8, 2019 — Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, today announced that it has entered into a definitive merger agreement to be acquired by Siemens Healthineers AG. Under the terms of the merger agreement, Siemens Medical Solutions, a wholly-owned subsidiary of Siemens Healthineers AG, a German stock listed company, will acquire all issued and outstanding shares of common stock of Corindus for $4.28 per share in cash, representing an aggregate purchase price of approximately $1.1 billion.